You should not use Azzalure during pregnancy. Treatment with Azzalure is not recommended if you are breastfeeding. If you are pregnant or think you may be pregnant or if you are breastfeeding, consult your doctor before using any medication.
Driving and operating machinery
You may experience blurred vision, muscle weakness, or generalized weakness after treatment with Azzalure.If this occurs, do not drive or operate machinery.
Azzalure can only be administered by doctors with the necessary qualifications and experience in this treatment and who have the appropriate equipment.
Your doctor will prepare and apply the injections. A vial of Azzalure must be used for a single patient and a single treatment session.
The recommended dose of Azzalure is:
The units used in different botulinum toxin products are not equal. The Speywood units of Azzalure are not interchangeable with other botulinum toxin products.
The effect of the treatment should be noticeable a few days after the injection.
Your doctor will decide on the appropriate interval between each Azzalure treatment. This interval must not be less than 12 weeks.
Azzalure is not indicated for patients under 18 years of age.
If you use more Azzalure than you should
If you receive more Azzalure than necessary, other muscles treated may begin to weaken. This may not occur immediately. If you experience these symptoms, inform your doctor as soon as possible.
In case of overdose or accidental administration, call the Toxicological Information Service, phone: 91 562 04 20 (indicating the medication and the amount administered).
Like all medicines, Azzalure may cause side effects, although not everyone will experience them.
Seek medical attention if:
Inform your doctor if you experience any of the following side effects:
For frown lines:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Unknown frequency (cannot be estimated with available data)
For lateral canthal lines:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Unknown frequency (cannot be estimated with available data)
These side effects usually occur within the first week after injections and do not last long. They are usually mild to moderate.
Very rarely, side effects with botulinum toxin in muscles other than those at the injection site have been reported. These include excessive muscle weakness, difficulty swallowing due to coughing and a sensation of choking when swallowing (if liquids or food enter the airways, respiratory problems such as pulmonary infections may occur). If this happens, inform your doctor immediately.
Reporting side effects:
If you experience any type of side effect, consult your doctor, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep Azzalure out of sight and reach of children.
Your doctor should not use Azzalure after the expiration date indicated on the label. The expiration date is the last day of the month indicated.
Store Azzalure in a refrigerator (2°C - 8°C). Do not freeze.
Your doctor will dissolve Azzalure in a liquid injection solution.
Once reconstituted, chemical and physical stability has been demonstrated for 24 hours between 2-8°C. From a microbiological standpoint, unless the reconstitution method excludes the risk of microbial contamination, the medication should be used immediately. In the event that it is not used immediately, the time and storage conditions once reconstituted are the responsibility of the user.
Composition of Azzalure
*Botulinum toxin type A fromClostridium botulinum(a bacterium)- hemagglutinin complex.
The Speywood units of Azzalure are specific to the product and are not interchangeable with other treatments containing botulinum toxin.
Appearance of the product and contents of the packaging
Azzalure is a powder for injectable solution. The packaging is 1 or 2 vials.
Azzalure is a white powder.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Ipsen Pharma, S.A.U. Gran Via de les Corts Catalanes 130-136. 08038, Barcelona - Spain
Local representative:
Laboratorios Galderma SA
Serrano Galvache, 56. 28033 Madrid - Spain
Tel: 902 02 75 95
Responsible for manufacturing:
Ipsen Manufacturing Ireland Limited
Blanchardstown Industrial Park
Blanchardstown, Dublin 15, Ireland
This prospectus has been approved in February 2025.
If you want more information, or are interested in the prospectus in a different format, contactLaboratorios Galderma SA, tel. 902 02 75 95.
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
-----------------------------------------------------------------------------------------------------------------
This information is intended solely for doctors or healthcare professionals:
Dosage and administration:
See section 3 of the Patient Information Leaflet.
Special precautions for disposal and other handling
Follow the usage, handling, and disposal instructions strictly.
The reconstitution should be performed in accordance with good practices, especially respecting aseptic conditions.
Azzalure should be reconstituted with a 9 mg/ml (0.9%) sodium chloride injectable solution.
In the dilution table below, the amount of 9 mg/ml (0.9%) sodium chloride injectable solution to be added to a vial of 125 U is indicated to obtain a transparent and colorless reconstituted solution with the following concentrations:
Amount of solvent added (sodium chloride solution 0.9%) for a vial of 125 U | Resulting dose |
0.63 ml 1.25 ml | 10 U for 0.05 ml 10 U for 0.1 ml |
To measure accurately the 0.63 ml or 1.25 ml, a graduated syringe with increments of 0.1 ml and 0.01 ml will be used.
RECOMMENDATIONS FOR DISPOSAL OF CONTAMINATED MATERIALS
Immediately after use and before disposal, the reconstituted Azzalure solution (in the vial or syringe) that has not been used should be inactivated with 2 ml of diluted sodium hypochlorite solution at 0.55% or 1% (Dakin solution).
The vials, syringes, and materials used should not be emptied, but should be deposited in suitable containers and disposed of according to local established procedures.
RECOMMENDATIONS IN CASE OF ACCIDENT DURING HANDLING OF BOTULINUM TOXIN
These usage, handling, and disposal instructions should be followed strictly.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.